Literature DB >> 27219238

Surgical Management of Polyostotic Craniofacial Fibrous Dysplasia: Long-Term Outcomes and Predictors for Postoperative Regrowth.

Alison M Boyce1, Andrea Burke, Carolee Cutler Peck, Craig R DuFresne, Janice S Lee, Michael T Collins.   

Abstract

BACKGROUND: The mainstay of treatment for craniofacial fibrous dysplasia is surgical; however, optimal indications and techniques are poorly understood, particularly in polyostotic disease and McCune-Albright syndrome. This study investigated surgical indications and risk factors for recurrence in a large cohort.
METHODS: One hundred thirty-three craniofacial fibrous dysplasia subjects in a natural history study were evaluated. Radiographic studies, operative reports, and clinical records were reviewed.
RESULTS: Thirty-six subjects underwent 103 craniofacial procedures (mean, 2.8 operations per subject), with 13.5 ± 10.5-year follow-up (range, 0 to 39 years). The most common indication was craniofacial deformity (n = 61 operations), including 36 initial operations (59 percent) and 26 reoperations (41 percent). Mean time to reoperation was 3.4 ± 3.2 years (range, 0.3 to 13.3 years). Regrowth occurred after 42 operations (68 percent), and was more frequent after operations in subjects with McCune-Albright syndrome growth hormone excess [22 of 25 operations (88 percent)] than without growth hormone excess [15 of 36 operations (58 percent); p = 0.02]. Of 11 subjects with growth hormone excess, nine (82 percent) were undiagnosed at the time of their initial operation. Regrowth was more frequent after debulking procedures [31 of 38 (82 percent)] than after more aggressive reconstructions [nine of 20 (45 percent); p = 0.007]. Eleven subjects underwent treatment for aneurysmal bone cysts, with recurrence in one subject. Eleven subjects underwent biopsies and none had complications or regrowth.
CONCLUSIONS: Craniofacial fibrous dysplasia regrowth and reoperation are common, particularly after debulking procedures. Outcomes are favorable for aneurysmal bone cysts and biopsies. McCune-Albright syndrome growth hormone excess is a risk factor for regrowth, and may be underdiagnosed in surgical patients. Surgeons should be aware of appropriate screening for endocrinopathies in fibrous dysplasia. These findings highlight the importance of a multidisciplinary approach to craniofacial fibrous dysplasia, and individualized care with long-term follow-up. CLINICAL QUESTION/LEVEL OF EVIDENCE: Therapeutic, IV.

Entities:  

Mesh:

Year:  2016        PMID: 27219238      PMCID: PMC5653228          DOI: 10.1097/PRS.0000000000002151

Source DB:  PubMed          Journal:  Plast Reconstr Surg        ISSN: 0032-1052            Impact factor:   4.730


  23 in total

Review 1.  Craniofacial fibrous dysplasia.

Authors:  Pat Ricalde; Kelly R Magliocca; Janice S Lee
Journal:  Oral Maxillofac Surg Clin North Am       Date:  2012-07-06       Impact factor: 2.802

2.  Aneurysmal bone cyst within fibrous dysplasia of the anterior skull base: continued intracranial extension after endoscopic resections requiring craniofacial approach with free tissue transfer reconstruction.

Authors:  Sunil Manjila; Chad A Zender; John Weaver; Mark Rodgers; Alan R Cohen
Journal:  Childs Nerv Syst       Date:  2013-02-26       Impact factor: 1.475

3.  An instrument to measure skeletal burden and predict functional outcome in fibrous dysplasia of bone.

Authors:  Michael T Collins; Harvey Kushner; James C Reynolds; Caroline Chebli; Marilyn H Kelly; Anurag Gupta; Beth Brillante; Arabella I Leet; Mara Riminucci; Pamela Gehron Robey; Paolo Bianco; Shlomo Wientroub; Clara C Chen
Journal:  J Bone Miner Res       Date:  2004-11-16       Impact factor: 6.741

4.  Radical treatment for fronto-orbital fibrous dysplasia: the chain-link fence.

Authors:  I R Munro; Y R Chen
Journal:  Plast Reconstr Surg       Date:  1981-06       Impact factor: 4.730

5.  Surgical treatment of fibrous dysplasia of the skull in children.

Authors:  Cormac O Maher; Jonathan A Friedman; Fredric B Meyer; James J Lynch; Krishnan Unni; Corey Raffel
Journal:  Pediatr Neurosurg       Date:  2002-08       Impact factor: 1.162

6.  The surgical treatment of fibrous dysplasia. With emphasis on recent contributions from cranio-maxillo-facial surgery.

Authors:  M T Edgerton; J A Persing; J A Jane
Journal:  Ann Surg       Date:  1985-10       Impact factor: 12.969

7.  Normal vision despite narrowing of the optic canal in fibrous dysplasia.

Authors:  Janice S Lee; Edmond FitzGibbon; John A Butman; Craig R Dufresne; Harvey Kushner; Shlomo Wientroub; Pamela G Robey; Michael T Collins
Journal:  N Engl J Med       Date:  2002-11-21       Impact factor: 91.245

8.  Age-dependent demise of GNAS-mutated skeletal stem cells and "normalization" of fibrous dysplasia of bone.

Authors:  Sergei A Kuznetsov; Natasha Cherman; Mara Riminucci; Michael T Collins; Pamela Gehron Robey; Paolo Bianco
Journal:  J Bone Miner Res       Date:  2008-11       Impact factor: 6.741

9.  Activating mutations of the stimulatory G protein in the McCune-Albright syndrome.

Authors:  L S Weinstein; A Shenker; P V Gejman; M J Merino; E Friedman; A M Spiegel
Journal:  N Engl J Med       Date:  1991-12-12       Impact factor: 91.245

10.  Surgery versus watchful waiting in patients with craniofacial fibrous dysplasia--a meta-analysis.

Authors:  Moran Amit; Michael T Collins; Edmond J FitzGibbon; John A Butman; Dan M Fliss; Ziv Gil
Journal:  PLoS One       Date:  2011-09-23       Impact factor: 3.240

View more
  15 in total

Review 1.  Fibrous dysplasia of bone: craniofacial and dental implications.

Authors:  A B Burke; M T Collins; A M Boyce
Journal:  Oral Dis       Date:  2016-09-01       Impact factor: 3.511

Review 2.  Fibrous Dysplasia of Bone and McCune-Albright Syndrome: A Bench to Bedside Review.

Authors:  Iris Hartley; Maria Zhadina; Micheal T Collins; Alison M Boyce
Journal:  Calcif Tissue Int       Date:  2019-04-29       Impact factor: 4.333

Review 3.  Head and neck manifestations of an undiagnosed McCune-Albright syndrome: clinicopathological description and literature review.

Authors:  Beatriz Lecumberri; José Juan Pozo-Kreilinger; Isabel Esteban; Mariana Gomes; Aránzazu Royo; Álvaro Gómez de la Riva; Guiomar Pérez de Nanclares
Journal:  Virchows Arch       Date:  2018-07-08       Impact factor: 4.064

Review 4.  DIAGNOSIS OF ENDOCRINE DISEASE: Mosaic disorders of FGF23 excess: Fibrous dysplasia/McCune-Albright syndrome and cutaneous skeletal hypophosphatemia syndrome.

Authors:  Luis F de Castro; Diana Ovejero; Alison M Boyce
Journal:  Eur J Endocrinol       Date:  2020-05       Impact factor: 6.664

5.  Association of Hearing Loss and Otologic Outcomes With Fibrous Dysplasia.

Authors:  Alison M Boyce; Carmen Brewer; Timothy R DeKlotz; Christopher K Zalewski; Kelly A King; Michael T Collins; H Jeffrey Kim
Journal:  JAMA Otolaryngol Head Neck Surg       Date:  2018-02-01       Impact factor: 6.223

Review 6.  The Clinical Spectrum of McCune-Albright Syndrome and Its Management.

Authors:  Tiahna Spencer; Kristen S Pan; Michael T Collins; Alison M Boyce
Journal:  Horm Res Paediatr       Date:  2019-12-19       Impact factor: 2.852

7.  Augmented reality navigation method for recontouring surgery of craniofacial fibrous dysplasia.

Authors:  Kai Liu; Yuan Gao; Ahmed Abdelrehem; Lei Zhang; Xi Chen; Le Xie; Xudong Wang
Journal:  Sci Rep       Date:  2021-05-11       Impact factor: 4.379

8.  18 F-NaF PET/CT IMAGING IN FIBROUS DYSPLASIA OF BONE.

Authors:  Georgios Z Papadakis; Georgios C Manikis; Apostolos H Karantanas; Pablo Florenzano; Ulas Bagci; Kostas Marias; Michael T Collins; Alison M Boyce
Journal:  J Bone Miner Res       Date:  2019-05-22       Impact factor: 6.390

9.  Extensive titanium mesh invasive cranial fibrous dysplasia.

Authors:  Ishu Bishnoi; Tushit Mewada; Satish Kumar Bansal; Geetika Duggal; Karandeep Singh
Journal:  Surg Neurol Int       Date:  2021-06-21

Review 10.  Fibrous Dysplasia/McCune-Albright Syndrome: A Rare, Mosaic Disease of Gα s Activation.

Authors:  Alison M Boyce; Michael T Collins
Journal:  Endocr Rev       Date:  2020-04-01       Impact factor: 19.871

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.